David Hackshall - CochLear Chief Officer
| CHEOY Stock | USD 98.91 0.76 0.76% |
Executive
Mr. David Hackshall serves as Chief Information Officer of the Company. He joined Cochlear in July 2015 as Cochlears first Chief Information Officer and has global responsibility for the Companys information technology strategy and management. Davids focus is to ensure Cochlear has the platforms in place to deliver and drive growth. This capability is critical in connecting Cochlear with both professionals and recipients, and evolving Cochlear into both a businesstobusiness as well as businesstocustomer organisation. Prior to Cochlear, David was Chief Information Officer at Wesfarmers Insurance Ltd and brings over 15 years of executive experience across the Communications, Logistics and Finance sectors. since 2015.
| Tenure | 10 years |
| Phone | 61 2 9428 6555 |
| Web | https://www.cochlear.com |
CochLear Management Efficiency
The company has return on total asset (ROA) of 0.0973 % which means that it generated a profit of $0.0973 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1713 %, meaning that it generated $0.1713 on every $100 dollars invested by stockholders. CochLear's management efficiency ratios could be used to measure how well CochLear manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Leverne Marsh | DexCom Inc | N/A | |
| Darleen Caron | Siemens Healthineers AG | 59 | |
| Shelly Selvaraj | DexCom Inc | 65 | |
| Cathy ORourke | Smith Nephew SNATS | 46 | |
| Joe Metzger | Smith Nephew SNATS | N/A | |
| Scott Leinenweber | Abbott Laboratories | 52 | |
| Donald Abbey | DexCom Inc | 58 | |
| Teri Lawver | DexCom Inc | 57 | |
| Andrew Senn | Integer Holdings Corp | 43 | |
| Dirksen Lehman | Edwards Lifesciences Corp | N/A | |
| Michael Brown | DexCom Inc | 55 | |
| Sabina Ewing | Abbott Laboratories | 51 | |
| Niels Wagner | Demant AS ADR | 52 | |
| MD FACC | Edwards Lifesciences Corp | N/A | |
| Melissa Brotz | Abbott Laboratories | N/A | |
| Michael Comilla | Abbott Laboratories | N/A | |
| Arnold Pinkston | Edwards Lifesciences Corp | 65 | |
| Gary Sorsher | Edwards Lifesciences Corp | 59 | |
| Steve Kane | Smith Nephew SNATS | N/A | |
| Dragana Bunjevac | Stryker | N/A | |
| Finn Haley | Edwards Lifesciences Corp | N/A | |
Management Performance
| Return On Equity | 0.17 | |||
| Return On Asset | 0.0973 |
CochLear ADR Leadership Team
Elected by the shareholders, the CochLear's board of directors comprises two types of representatives: CochLear inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CochLear. The board's role is to monitor CochLear's management team and ensure that shareholders' interests are well served. CochLear's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CochLear's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stuart Sayers, President - Services | ||
| David Hackshall, Chief Officer | ||
| MBA BE, MD, CEO | ||
| Anthony Bishop, President - Asia Pacific | ||
| Dean Phizacklea, Senior Vice President Global Marketing | ||
| Richard MBA, Pres EMEA | ||
| Jennifer Stevenson, VP Brand | ||
| Jan Eng, Chief Officer | ||
| Kristina Devon, VP Relations | ||
| Lisa Aubert, Pres America |
CochLear Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is CochLear a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.17 | |||
| Return On Asset | 0.0973 | |||
| Profit Margin | 0.18 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 9.05 B | |||
| Shares Outstanding | 131.56 M | |||
| Price To Earning | 49.26 X | |||
| Price To Book | 8.15 X | |||
| Price To Sales | 5.55 X | |||
| Revenue | 1.65 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CochLear Pink Sheet Analysis
When running CochLear's price analysis, check to measure CochLear's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CochLear is operating at the current time. Most of CochLear's value examination focuses on studying past and present price action to predict the probability of CochLear's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CochLear's price. Additionally, you may evaluate how the addition of CochLear to your portfolios can decrease your overall portfolio volatility.